Spondyloarthritis & psoriatic arthritis
Effects of upadacitinib on enthesitis in patients with psoriatic arthritis: a post hoc analysis of SELECT-PsA 1 and 2 trials
Authors' conclusion
UPA15 is associated with a comprehensive improvement in enthesitis, with improvements observed after 12 weeks of treatment. Additionally, treatment with UPA15 was associated with maintaining an enthesitis-free state after resolution and protection against new-onset enthesitis.
Study context
- Population
- Patients with PsA and inadequate response/intolerance to ≥1 non-biologic DMARD (SELECT-PsA 1) or ≥1 biologic DMARD (SELECT-PsA 2)317 switched placebo to UPA15
- Comparison
- UPA15 vs placebo; adalimumab 40 mg every other week also an arm
- UPA15n = 639
- Placebon = 635reference
- Primary endpoint
- Enthesitis resolution (LEI and SPARCC index)
- Follow-up
- Week 24
Methodological detailsphase 3
- Phase 3
Primary result
As reported in the abstract
Enthesitis resolution
| Outcome | UPA15 | Placebo |
|---|---|---|
| LEI resolution | 59.8% | 38.0% |
| SPARCC resolution | 50.6% | 31.5% |
Further findings
| Outcome | UPA15 | Placebo |
|---|---|---|
| Change in LEI and SPARCC index · week 24 | ||
| LEI change | −1.7 | −1.0 |
| SPARCC change | −3.4 | −1.9 |
Change in Leeds Enthesitis Index (LEI) and Spondyloarthritis Research Consortium of Canada (SPARCC) index · week 24
- Improvements maintained through week 56; observed after 12 weeks of UPA15
Enthesitis-free at week 56 among patients without enthesitis (LEI = 0) at baseline on UPA15
- Enthesitis-free
- Over 90%
No recurrence at week 56 among patients achieving resolution (LEI = 0) at week 24 on UPA15
- Recurrence prevented
- >80%
Original publication
Effects of upadacitinib on enthesitis in patients with psoriatic arthritis: a post hoc analysis of SELECT-PsA 1 and 2 trials. Rheumatology (Oxford). Published 8 February 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →